PE20060768A1 - PHARMACEUTICAL COMPOSITION INCLUDING HYDROCHLOROTHIAZIDE AND TELMISARTANE - Google Patents
PHARMACEUTICAL COMPOSITION INCLUDING HYDROCHLOROTHIAZIDE AND TELMISARTANEInfo
- Publication number
- PE20060768A1 PE20060768A1 PE2005001465A PE2005001465A PE20060768A1 PE 20060768 A1 PE20060768 A1 PE 20060768A1 PE 2005001465 A PE2005001465 A PE 2005001465A PE 2005001465 A PE2005001465 A PE 2005001465A PE 20060768 A1 PE20060768 A1 PE 20060768A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- hydrochlorothiazide
- composition including
- telmisartane
- composition
- Prior art date
Links
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002003 hydrochlorothiazide Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 abstract 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 239000005537 C09CA07 - Telmisartan Substances 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960005187 telmisartan Drugs 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 229920002261 Corn starch Polymers 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000008120 corn starch Substances 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 235000010356 sorbitol Nutrition 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicinal Preparation (AREA)
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE 80 MG DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA II TAL COMO EL TELMISARTANO Y 25 MG DE UN DIURETICO TAL COMO HIDROCLOROTIAZIDA. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA QUE PUEDE DIVIDIRSE EN MITADES QUE COMPRENDE 160 MG DE TELMISARTANO Y 50 MG DE HIDROCLOROTIAZIDA. LA COMPOSICION PUEDE CONTENER, ADEMAS, HIDROXIDO DE SODIO, MEGLUMINA, POVIDONA, SORBITOL, ESTEARATO DE MAGNESIO, LACTOSA MONOHIDRATADA, CELULOSA MICROCRISTALINA, ALMIDON DE MAIZ, ENTRE OTROS. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA HIPERTENSION, ACCIDENTES CEREBRO VASCULARES, INSUFICIENCIA CARDIACA CONGESTIVA, RESISTENCIA A LA INSULINA, ENTRE OTROSREFERRING TO A PHARMACEUTICAL COMPOSITION INCLUDING 80 MG OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST SUCH AS TELMISARTAN AND 25 MG OF A DIURETIC SUCH AS HYDROCHLOROTHIAZIDE. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION THAT CAN BE DIVIDED INTO HALVES, INCLUDING 160 MG OF TELMISARTAN AND 50 MG OF HYDROCHLOROTHIAZIDE. THE COMPOSITION MAY ALSO CONTAIN SODIUM HYDROXIDE, MEGLUMIN, POVIDONE, SORBITOL, MAGNESIUM STEARATE, MONOHYDRATED LACTOSE, MICROCRYSTALLINE CELLULOSE, CORN STARCH, AMONG OTHERS. SUCH COMPOSITION IS USEFUL FOR THE TREATMENT OF HYPERTENSION, VASCULAR BRAIN ACCIDENTS, CONGESTIVE HEART FAILURE, INSULIN RESISTANCE, AMONG OTHERS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63706204P | 2004-12-17 | 2004-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060768A1 true PE20060768A1 (en) | 2006-09-29 |
Family
ID=35589356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001465A PE20060768A1 (en) | 2004-12-17 | 2005-12-15 | PHARMACEUTICAL COMPOSITION INCLUDING HYDROCHLOROTHIAZIDE AND TELMISARTANE |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1827424A1 (en) |
| JP (1) | JP2008524136A (en) |
| KR (1) | KR20070097511A (en) |
| CN (1) | CN101080225A (en) |
| AR (1) | AR052052A1 (en) |
| AU (1) | AU2005315855A1 (en) |
| BR (1) | BRPI0519656A2 (en) |
| CA (1) | CA2589493A1 (en) |
| EA (1) | EA200701159A1 (en) |
| IL (1) | IL183944A0 (en) |
| NO (1) | NO20072325L (en) |
| PE (1) | PE20060768A1 (en) |
| TW (1) | TW200637546A (en) |
| UY (1) | UY29274A1 (en) |
| WO (1) | WO2006063737A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| US8637078B2 (en) * | 2005-11-24 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Bilayer tablet comprising telmisartan and diuretic |
| EP1970053A1 (en) * | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
| SI2180882T1 (en) * | 2007-10-19 | 2013-05-31 | Otsuka Pharmaceutical Co., Ltd. | Solid matrix pharmaceutical preparation |
| US20100247649A1 (en) | 2007-10-30 | 2010-09-30 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide |
| PL2252273T3 (en) | 2008-03-19 | 2017-07-31 | Ratiopharm Gmbh | Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic |
| BRPI0916847A2 (en) | 2008-07-31 | 2016-02-10 | Takeda Pharmaceutical | solid preparation, and methods for stabilizing a compound and for improving the dissolution property of a compound. |
| GB0822170D0 (en) * | 2008-12-04 | 2009-01-14 | Arrow Int Ltd | Telmisartan with diuretic formulations |
| ES2415357T3 (en) | 2009-06-19 | 2013-07-25 | Krka Tovarna Zdravil, D.D., Novo Mesto | Procedure for the preparation of telmisartan |
| EP2448575A2 (en) * | 2009-07-02 | 2012-05-09 | Bilgic Mahmut | Pharmaceutical composition increasing solubility and stability |
| EP2448576A2 (en) * | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Solubility enhancing pharmaceutical composition |
| TR200906506A2 (en) | 2009-08-24 | 2011-03-21 | Bi̇lgi̇ç Mahmut | Solid dosage forms containing telmisartan. |
| WO2011161123A2 (en) | 2010-06-21 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Multilayer pharmaceutical tablet comprising telmisartan and a diuretic |
| WO2014119767A1 (en) * | 2013-01-31 | 2014-08-07 | 沢井製薬株式会社 | Multilayer tablet containing telmisartan and hydrochlorothiazide |
| WO2015012205A1 (en) * | 2013-07-23 | 2015-01-29 | 第一三共株式会社 | Medicine for preventing or treating hypertension |
| CN106562973A (en) * | 2016-11-06 | 2017-04-19 | 成都先先先生物科技有限公司 | Anti-hypertension medicine compound preparation |
| CN107501192A (en) * | 2017-08-15 | 2017-12-22 | 中国科学院上海药物研究所 | The eutectic of Telmisartan and Hydrochioro |
| CN108653227A (en) * | 2018-08-09 | 2018-10-16 | 湖北舒邦药业有限公司 | A kind of Telmisartan hydrochlorothiazide tablets and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4229085C2 (en) * | 1992-09-01 | 1996-07-11 | Boehringer Mannheim Gmbh | Elongated, divisible tablet |
| EA007614B1 (en) * | 2002-01-16 | 2006-12-29 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Bilayer pharmaceutical tablet and method for producing thereof |
-
2005
- 2005-12-09 CN CNA2005800434334A patent/CN101080225A/en active Pending
- 2005-12-09 CA CA002589493A patent/CA2589493A1/en not_active Abandoned
- 2005-12-09 EA EA200701159A patent/EA200701159A1/en unknown
- 2005-12-09 WO PCT/EP2005/013224 patent/WO2006063737A1/en active Application Filing
- 2005-12-09 BR BRPI0519656-6A patent/BRPI0519656A2/en not_active Application Discontinuation
- 2005-12-09 AU AU2005315855A patent/AU2005315855A1/en not_active Abandoned
- 2005-12-09 EP EP05814002A patent/EP1827424A1/en not_active Withdrawn
- 2005-12-09 JP JP2007545905A patent/JP2008524136A/en active Pending
- 2005-12-09 KR KR1020077016354A patent/KR20070097511A/en not_active Withdrawn
- 2005-12-15 PE PE2005001465A patent/PE20060768A1/en not_active Application Discontinuation
- 2005-12-16 TW TW094144909A patent/TW200637546A/en unknown
- 2005-12-16 AR ARP050105303A patent/AR052052A1/en unknown
- 2005-12-20 UY UY29274A patent/UY29274A1/en not_active Application Discontinuation
-
2007
- 2007-05-04 NO NO20072325A patent/NO20072325L/en not_active Application Discontinuation
- 2007-06-14 IL IL183944A patent/IL183944A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101080225A (en) | 2007-11-28 |
| TW200637546A (en) | 2006-11-01 |
| KR20070097511A (en) | 2007-10-04 |
| CA2589493A1 (en) | 2006-06-22 |
| AR052052A1 (en) | 2007-02-28 |
| IL183944A0 (en) | 2007-10-31 |
| EA200701159A1 (en) | 2007-12-28 |
| NO20072325L (en) | 2007-07-06 |
| BRPI0519656A2 (en) | 2009-03-03 |
| JP2008524136A (en) | 2008-07-10 |
| AU2005315855A1 (en) | 2006-06-22 |
| UY29274A1 (en) | 2006-07-31 |
| EP1827424A1 (en) | 2007-09-05 |
| WO2006063737A1 (en) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060768A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING HYDROCHLOROTHIAZIDE AND TELMISARTANE | |
| CL2008003595A1 (en) | Nitrogen heterocyclic compounds, tachykinin receptor antagonists; pharmaceutical agent comprising the compound; and use in the prophylaxis or treatment of a lower urinary tract disease, a gastrointestinal disease, or a disease of the central nervous system. | |
| BRPI0507887A (en) | multilayer tablet | |
| PH12012501282A1 (en) | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof | |
| DOP2004000907A (en) | PHARMACEUTICAL PROCEDURES AND COMPOSITIONS TO TREAT ATEROSCLEROSIS DISLIPIDEMIAS AND RELATED AFFECTIONS | |
| WO2011014587A3 (en) | Ophthalmic pharmaceutical compositions of dp2 receptor antagonists | |
| AU2018335259A1 (en) | High dosage valbenazine formulation and compositions, methods, and kits related thereto | |
| CY1109719T1 (en) | PREPARATION 1 - [(3-Hydroxy-Adamant-1-ylamino) -acetyl] -pyrrolidine-2- (S) -CLONONitrile MODIFIED FREEDOM | |
| PE20020082A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1) | |
| MX2012000317A (en) | Hot-melt extruded controlled release dosage form. | |
| AR069031A1 (en) | COMPOSITION | |
| ATE415947T1 (en) | USE OF STARCH WITH CLAVED SIDE CHAINS IN EXTRUDING/SPHERONIZATION OF PHARMACEUTICAL PELLETS | |
| EA201001312A1 (en) | SOLID PHARMACEUTICAL COMPOSITION CONTAINING NEPEPTIDE ANTAGONIST OF ANGIOTENSIN II RECEPTOR AND DIURETIC | |
| AR066168A1 (en) | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS | |
| UY30461A1 (en) | PHARMACEUTICAL COMPOSITION FOR ANTI-CONCEPTION AND TO REDUCE THE RISK OF CONGENITAL MALFORMATIONS. | |
| AR061233A1 (en) | FORMULATION OF PROLONGED LIBERATION OF NALTREXONA | |
| PE20120421A1 (en) | PHARMACEUTICAL COMPOSITION WHICH INCLUDES HAPPINESS | |
| PE20020617A1 (en) | COMPOSITION INCLUDING AN AT1 RECEPTOR ANTAGONIST AND AN INSULIN SECRETION POTENTIAL OR AN INSULIN SENSITIZER | |
| ATE451097T1 (en) | VALSARTAN FORMULATIONS | |
| CY1113484T1 (en) | 3-FENYLYPYRAZOLO [5,1-B] THIAZOLIUM COMPOUND | |
| UA100883C2 (en) | Use of dronedarone or one of its pharmaceutically acceptable salts for preparing a medicament for the treatment of patients with arrhythmia and an increased creatinine level due to dronedarone administration | |
| AR063255A1 (en) | FORMULATION OF PHARMACEUTICAL TABLETS | |
| CR11766A (en) | IMINOPIRIDINE DERIVATIVES AND USE OF THE SAME | |
| WO2009001661A1 (en) | Medicinal agent for prevention or treatment of alzheimer's disease | |
| AR072477A1 (en) | PHARMACEUTICAL FORMULATION OF EPROSARTAN. USE. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |